Clin2
NCT07190222Possibly a fitRecruiting

New medicine for COPD with frequent flare-ups

Chronic Obstructive Pulmonary Disease

Treatments studied

Part of Lungs & breathing clinical trials.

This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
942 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • You are between 40 and 80 years old.
  • You have had COPD for at least 1 year, diagnosed by a doctor.
  • You are a current or former smoker with at least a 10 pack-year smoking history (e.g., 1 pack a day for 10 years).
  • You have had at least 2 moderate flare-ups or 1 severe flare-up in the past year.
  • You are already taking a combination inhaler (three types of medicine) for COPD and have been on it for at least 12 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07190209Recruiting· Phase 3
Testing lunsekimig for COPD with frequent flare-ups

This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.

Chandler, Arizona
NCT07793409Not yet recruiting· Phase 3
Long-term safety study of lunsekimig for COPD

This study is a long-term follow-up for people with COPD who have already completed an earlier lunsekimig study. It aims to check the safety and effectiveness of the treatment over a longer period.

NCT06547333Not yet recruiting· Phase 2/Phase 3
Study of CM310 for frequent COPD flare-ups

This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.

NCT07418736Recruiting· Phase 2
CM326 for moderate to severe COPD

This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.

Beijing, Beijing Municipality
NCT06334575Recruiting· Phase 4
COPD treatment study based on eosinophil levels

This trial tests if inhaled corticosteroids (ICS) work better for COPD patients with different eosinophil levels. You must already be taking two long-acting bronchodilators and have stopped smoking for at least 6 months.

Marburg
NCT06980142Not yet recruiting· Phase 2
CM512 for moderate-to-severe COPD

This study tests a new medication called CM512 for people with moderate-to-severe COPD who still have flare-ups despite using their regular inhalers. It aims to see if adding this treatment can reduce flare-ups and improve quality of life.

Hear when a new Chronic Obstructive Pulmonary Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.